Long-Term Used of Benzalkonium Chloride Preservative Antiglaucoma Eye Drops (Studies on the Expression of Matrix-Metalloproteinase-1 and Tissue Inhibitor Matrix Metalloproteinase-1)
ABSTRACT: The aim of this
study is to compare the mean expression of Matrix metalloproteinase-1 (MMP-1)
and the mean expression of Tissue Inhibitor Matrix metalloproteinase-1 (TIMP-1)
from conjunctiva of the long-term preservative antiglaucoma BAC eye drops user
with the non-user of preservative antiglaucoma BAC. This cross-sectional study
design was held in Dr. Sardjito General Hospital and Dr.Yap Eye Hospital
Yogyakarta from November 2009 until August 2010. From the total 32 conjunctival
tissue biopsies, 17 samples were derived from the preservative antiglaucoma BAC
user group and 15 samples were derived from control conjunctival. The
expression of MMP-1 and TIMP-1 in both groups were detected by
immunohistochemistry with monoclonal antibody anti-human MMP-1 andanti-human
TIMP-1. The mean expression of MMP-1 from the long terms preservative
antiglaucoma eye drops BAC user group was 9.22 ± 8.11% and the expression of
TIMP-1 was 2.75 ± 2.36%. In the expression control group, MMP-1 was 1.02 ±
0.71% and the expression of TIMP-1 was 0.46 ± 0.22%. There was a correlation
between the number of antiglaucoma drugs used and TIMP-1 expression (r =
–0.623) with significancy at 0,008. The expression of MMP-1 and TIMP-1 in the
long term preservative antiglaucoma eye drops BAC user group is higher than the
expression of the control group with significantly at p < 0.001.
Penulis: Muhammad Ali Faisal,
Retno Ekantini, Siti Sundari
Kode Jurnal: jpkedokterandd100021
